

References

1. Pedersen CA, Schneider PJ, Scheckelhoff DJ. [ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing-2004](#). *Am J Health-Syst Pharm*. 2005; 62:378-90.
2. Nester TM, Hale LS. [Effectiveness of a pharmacists-acquired medication history in promoting patient safety](#). *Am J Health-Syst Pharm* 2002;59:2221-2225.
3. Gurwich EL. [Comparison of medication histories acquired by pharmacists and physicians](#). *Am J Hosp Pharm* 1983;40:1541-2.
4. Badowski SA, Rosenbloom D, Dawson PH. [Clinical importance of pharmacists-obtained medication histories using a validated questionnaire](#). *Am J Hosp Pharm* 1984;41:731-2.
5. Titcombe LC. The pharmacist's role in drug history taking. *Br J Pharm Pract* 1989;11:186-95.
6. Truitt CA, Longe L, Taylor AT. [An evaluation of a medication history method](#). *Drug IntelClin Pharm* 1982;16:592-595.
7. LaPointe NM, Jollis JG. [Medication errors in hospitalized cardiovascular patients](#). *Arch Intern Med* 2003; 163:1461-66.
8. Gleason KM, Groszek JM, Sullivan C et al. [Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients](#). *Am J Health Syst Pharm*. 2004; 61(16):1689-95.
9. Cornish PL, Knowles SR, Marchesano R, Tam V, Shadowitz S, Juurlink DN, Etchells EE. [Unintended Medication Discrepancies at the Time of Hospital Admission](#). *Arch Intern Med*. 2005;165:424-429.
10. Pronovost P, Weast B, Schwarz M, Wyskiel RM, Prow D, Milanovich SN, Berenholtz S, Dorman T, Lipsett P. [Medication reconciliation: a practical tool to reduce the risk of medication errors](#). *J Crit Care*. 2003;18(4):201-5.
11. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: dispensing and administration-2005. *Am J Health-Syst Pharm*. 2006 [in press].
12. Leape LL, Cullen DJ, Clapp MD, et al. [Pharmacist participation on physician rounds and adverse drug events in the intensive care unit](#). *JAMA* 1999;282:267-70.
13. Gattis W, Hasselblad V, Whellan D, et al. [Reduction in Heart Failure events by the addition of a clinical pharmacist to the heart failure management team](#). *Arch Intern Med*. 1999;159:1939-45.

14. Luzier AB, Forrest A, Feuerstein SG, et al. [Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization](#). *Am J Cardiol* 2000;86:519-23.
15. Kaushal R, Bates DW, Landrigan C, et al. [Medication errors and adverse drug events in pediatric inpatients](#). *JAMA* 2001; 285(16):2114-20.
16. Kucukarslan SN, Peters M, Mlynarek M, et al. [Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units](#). *Arch Intern Med* 2003; 163: 2014-8.
17. Scarsi KK, Fotis MA, Noskin Ga. [Pharmacists participation in medical rounds reduces medication errors](#). *Am J Health-Syst Pharm* 2002;59:2089-92.
18. Dooley MJ, Allen KM, Doecke CJ et al. [A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals](#). *Br J Clin Pharmacol*. 2004; 57(4):513-21.
19. Hammond RW, Schwartz AH, Campbell MJ et al. [Collaborative drug therapy management by pharmacists---2003](#). *Pharmacotherapy*. 2003; 23(9):1210-25.
20. Punekar Y, Lin SW, Thomas J III. [Progress of pharmacist collaborative practice: status of state laws and regulations and perceived impact of collaborative practice](#). *J Am Pharm Assoc*. 2003; 43(4):503-10.
21. Al-Rashed SA, Wright DJ, Roebuck N, et al. [The value of inpatient pharmaceutical counseling to elderly patients prior to discharge](#). *British Journal of Clinical Pharmacology* 2002; 54:657
22. Calabrese AT, Cholka K, Lenhart SE et al. [Pharmacist involvement in a multidisciplinary inpatient medication education program](#). *Am J Health Syst Pharm*. 2003; 60(10):1012-8.
23. American Society of Health System Pharmacists. [Top Patient Concerns 2002: Omnibus Survey Results](#).
24. The National Patient Safety Foundation. [National agenda for action: Patients and families in patient safety. Nothing about me, without me](#). 2004 Jan 12.
25. Carmichael JM, Alvarez A, Chaput R et al. [Establishment and outcomes of a model primary care pharmacy service system](#). *Am J Health-Syst Pharm*. 2004; 61(5):472-82.

26. Till LT, Voris JC, Horst JB. [Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting.](#) *J Manag Care Pharm.* 2003; 9(3):269-73.
27. Kuo GM, Buckley TE, Fitzsimmons DS et al. [Collaborative drug therapy management services and reimbursement in a family medicine clinic.](#) *Am J Health Syst Pharm.* 2004; 61(4):343-54.
28. Knapp KK, Okamoto MP, Black BL. [ASHP survey of ambulatory care pharmacy practice in health systems--2004.](#) *Am J Health Syst Pharm.* 2005; 62(3):274-84.
29. Chiquette E, Amato MG, Bussey HI. [Comparison of an anticoagulation clinic with usual medical care.](#) *Arch Inter Med.* 1998;158:1641-47.
30. Willey ML, Chagan L, Sisca TS, et al. [A pharmacist-managed anticoagulation clinic: Six-year assessment of patient outcomes.](#) *Am J Health Syst Pharm* 2003;60(10):1033-7.
31. Tschol N, Lai DK, Tilley JA, et al. [Comparison of physician-and pharmacist-managed warfarin sodium treatment in open heart surgery patients.](#) *Can J Cardiol.* 2003 Nov;19(12):1413-7.
32. Carter BL, Malone DC, Valuck RJ, et al. [The IMPROVE study: Background and study design. Impact of managed pharmaceutical care on resource utilization and outcomes in veterans affairs medical centers.](#) *Am J Health Syst Pharm.* 1998 Jan 01;55(1):62-7.
33. Ellis SL, Carter BL, Malone DC, Billups SJ, et al. [Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study.](#) *Pharmacotherapy* 2000 Dec;20(12):1508-16.
34. Carter BL. [Implementing the new guidelines for hypertension: JNC 7, ADA, WHO-ISH.](#) *J Manag Care Pharm.* 2004; 10(5 Suppl A):S18-25.
35. Murray MD, Young JM, Morrow DG et al. [Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure.](#) *Am J Geriatr Pharmacother.* 2004; 2(1):53-65.
36. Patel HR, Pruchnicki MC, Hall LE. [Assessment for chronic kidney disease service in high-risk patients at community health clinics.](#) *Ann Pharmacother.* 2005; 39(1):22-7.
37. Isetts BJ, Brown LM, Schondelmeyer SW, Lenarz LA. [Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals.](#) *Arch Intern Med* 2003; 163:1813-20.

38. Crotty M, Rowett D, Spurling L et al. [Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial.](#) *Am J Geriatr Pharmacother.* 2004; 2(4):257-64.
39. [ASHP guidelines on the pharmacist's role in the development, implementation, and assessment of critical pathways.](#) *Am J Health Syst Pharm.* 2004; 61(9):939-45.
40. Ryan TJ, Antman, Brooks NH, et al. [1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.](#) *J Am Coll Cardiol* 1999 Sep;34(3):890-911.
41. Scott IA, Denaro CP, Bennett CJ et al. [Achieving better in-hospital and after-hospital care of patients with acute cardiac disease.](#) *Med J Aust.* 2004; 180(10 Suppl):S83-8.
42. Masoudi FA, Rathore SS, Wang Y et al. [National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.](#) *Circulation.* 2004; 110(6):724-31.
43. Smith NL, Chan JD, Rea TD et al. [Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure.](#) *Am Heart J.* 2004; 148(4):710-7.
44. Tsuyuki RT, Fradette M, Johnson JA et al. [A multicenter disease management program for hospitalized patients with heart failure.](#) *J Card Fail.* 2004; 10(6):473-80.
45. Zhang H, Alexander JA, Luttrell J et al. [Data feedback and clinical process improvement in acute myocardial infarction.](#) *Am Heart J.* 2005; 149(5):856-61.
46. [American Society of Health-System Pharmacists. ASHP Therapeutic Position Statement on the use of B-blockers in survivors of acute myocardial infarction.](#) *Am J Health-Syst Pharm.* 2002;59:2226-32.
47. Bunch TJ, Muhlestein JB, Bair TL et al. [Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.](#) *Am J Cardiol.* 2005; 95(7):827-31. (3.4)

48. Antithrombotic Trialist's Collaborations. [Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients](#). *BMJ*. 2002;324:71-86.
49. Saseen JJ. [ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events](#). *Am J Health Syst Pharm*. 2005 Jul 1;62(13):1398-405.
50. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. [Intensive lipid lowering with atorvastatin in patients with stable coronary disease](#). *N Engl J Med*. 2005;352(14):1425-35. Epub 2005 Mar 8.
51. [Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults \(Adult Treatment Panel III\) Full Report](#). Department of Health and Human Services. Public Health Service. National Institute of Health. National Heart, Lung and Blood Institute. NIH Publication No. 02-5215 September 2002.
52. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. [Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines](#). *Circulation*. 2004;110(2):227-39.
53. Olson KL, Rasmussen J, Sandhoff BG, Merenich JA; Clinical Pharmacy Cardiac Risk Service Study Group. [Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization](#). *Arch Intern Med*. 2005;165(1):49-54.
54. Herbert D, Aronow, MD, MPH; Gian M. Novaro, MD; Michael S. Lauer, MD; Danielle M. Brennan, MS; A. Michael Lincoff, MD; Eric J. Topol, MD; Dean J. Kereiakes, MD; Steven E. Nissen, MD. [In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization: A Propensity Analysis](#). *Arch Intern Med*. 2003;163:2576-2582.
55. American Diabetes Association. [Diabetes Care](#). 2005;28(Suppl. 1):S4- S36.
56. [American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control](#). *Endocr Pract*. 2002;8(Suppl. 1):5-11.
57. [ASHP Therapeutic Position Statement on Strict glycemic control in patients with diabetes](#). *Am J Health-Syst Pharm* 2003;60: 2357-62.
58. Wasserfallen JB, Butschi AJ, Muff P et al. [Format of medical order sheet improves security of antibiotics prescription: The experience of an intensive care unit](#). *Crit Care Med*. 2004; 32(3):655-9.

59. United States Pharmacopeial Convention. [USP General Chapter \(797\) Pharmaceutical Compounding-Sterile Preparations. January 1, 2005.](#) (USP 27-NF 22)
60. [ASHP Guidelines on Quality Assurance for pharmacy prepared sterile products.](#) *Am J Health-Syst Pharm.* 2000 57:1150-69.
61. [ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery.](#) *Am J Health-Syst Pharm* 1999;56:1839-88.
62. Bratzler DW, Houck PM; Surgical Infection Prevention Guideline Writers Workgroup. [Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.](#) *Am J Surg.* 2005 Apr;189(4):395-404.
63. Bratzler DW, Houck PM, Richards C, Steele L, Dellinger EP, Fry DE, Wright C, Ma A, Carr K, Red L. [Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project.](#) *Arch Surg.* 2005 Feb;140(2):174-82.
64. Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup; American Academy of Orthopaedic Surgeons; American Association of Critical Care Nurses; American Association of Nurse Anesthetists; American College of Surgeons; American College of Osteopathic Surgeons; American Geriatrics Society; American Society of Anesthesiologists; American Society of Colon and Rectal Surgeons; American Society of Health-System Pharmacists; American Society of PeriAnesthesia Nurses; Ascension Health; Association of periOperative Registered Nurses; Association for Professionals in Infection Control and Epidemiology; Infectious Diseases Society of America; Medical Letter; Premier; Society for Healthcare Epidemiology of America; Society of Thoracic Surgeons; Surgical Infection Society. [Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.](#) *Clin Infect Dis.* 2004 Jun 15;38(12):1706-15. Epub 2004 May 26.
65. Blair R. [Medication transformation: pharmacists on the floor. A Midwest healthcare system takes bar code technology to new heights, as part of an enterprise initiative to optimize patient safety.](#) *Health Manag Technol.* 2004; 25(10):26, 28, 30.
66. Oren E, Shaffer ER, Guglielmo BJ. [Impact of emerging technologies on medication errors and adverse drug events.](#) *Am J Health Syst Pharm.* 2003; 60(14):1447-58. (5.2, 5.3)
67. Chung K, Choi YB, Moon S. [Toward efficient medication error reduction: error-reducing information management systems.](#) *J Med Syst.* 2003; 27(6):553-60.
68. Kester M. Bar coding at the bedside. [New England hospital implements an automated point-of-care medication administration system to reduce medication errors and their associated complications.](#) *Health Manag Technol.* 2004; 25(5):42-4.

69. Hagland M. [Safe ways. Hospitals looking to improve patient safety are turning to CPOE, bar coding and e-prescribing.](#) *Healthc Inform.* 2004; 21(8):20-5.
70. Phillips MT, Berner ES. [Beating the system—pitfalls of bar code medication administration.](#) *J Healthc Inf Manag.* 2004; 18(4):16-8.
71. Bates DW, Leape LL, Cullen DJ et al. [Effect of computerized physician order entry and a team intervention on prevention of serious medication errors.](#) *JAMA* 1998, 280:1311-6.
72. Bates DW, Teich JM, Lee J, et al. [The impact of computerized physician order entry on medication error prevention.](#) *J Am Med Inform Assoc* 1999;6:313-321.
73. Bates DW, Boyle DL, Vander Vliet MB, et al. [Relationship between medication errors and adverse drug events.](#) *J Gen Intern Med* 1995;4:199-205.
74. Potts Al, Barr Fe, Gregory DF, at al. [Computerized physician order entry and medication errors in a pediatric critical care unit.](#) *Pediatrics* 2004;113:59-63.
75. Kaushal R, Bates DW, Landrigan C, at al. [Medication errors and adverse drug events in pediatric inpatients.](#) *JAMA* 2001;285:2114-20.
76. Institute of Medicine. [Key capabilities of an electronic health record system: Letter Report, Committee on Data Standards for Patient Safety, Board of Health Care Services, Institute of Medicine.](#) Pages 1-31. (Dated 7/31/03).
77. Kawamoto K, Lobach DF. [Clinical decision support provided within physician order entry systems: a systematic review of features effective for changing clinician behavior.](#) *AMIA Annu Symp Proc.* 2003; 361-5.
78. Krampera M, Venturini F, Benedetti F et al. [Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions.](#) *Br J Haematol.* 2004; 125(1):50-7.
79. Bobb A, Gleason K, Husch M et al. [The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry.](#) *Arch Intern Med.* 2004; 164(7):785-92.
80. Galanter WL, Polikaitis A, DiDomenico RJ. [A trial of automated safety alerts for inpatient digoxin use with computerized physician order entry.](#) *J Am Med Inform Assoc.* 2004; 11(4):270-7.

81. Handler JA, Feied CF, Coonan K et al. [Computerized physician order entry and online decision support](#). *Acad Emerg Med*. 2004; 11(11):1135-41.
82. DiFrancesco M, Andrew T. [Alamance Regional Medical Center improves patient safety with CPOE](#). *J Healthc Inf Manag*. 2004; 18(1):18-23.
83. Koppel R, Metlay JP, Cohen A et al. [Role of computerized physician order entry systems in facilitating medication errors](#). *JAMA*. 2005; 293(10):1197-203.
84. Rosenbloom ST, Geissbuhler AJ, Dupont WD et al. [Effect of CPOE use interface design on user-initiated access to educational and patient information during clinical care](#). *J Am Med Inform Assoc*. 2005; (in press).
85. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, Sam J, Haynes RB. [Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review](#). *JAMA*. 2005;293(10):1223-38.
86. Senholzi C, Gottlieb J. [Pharmacist interventions after implementation of computerized prescriber order entry](#). *Am J Health Syst Pharm*. 2003;60(18):1880-2.
87. Fair MA, Pane F. [Pharmacist interventions in electronic drug orders entered by prescribers](#). *Am J Health Syst Pharm*. 2004;61(12):1286-8.
88. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. [Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success](#). *BMJ*. 2005;330(7494):765. Epub 2005 Mar 14.
89. [ASHP Statement on the pharmacist's role in infection control](#). *Am J Health-Syst Pharm*. 1998 55:1724-6.
90. [ASHP Guidelines on the pharmacist's role in immunization](#). *Am J Health-Syst Pharm*. 2003; 60:1371-7.
91. [American Medical Association and Centers for Disease Control urges influenza vaccination for health care workers](#). November 21, 2003.
92. [ADA: Clinical Practice Recommendations 2004: Pneumococcal Immunizations in Diabetes \(Position statement\)](#). *Diabetes Care* 2004;27 (suppl 1).

93. [ASHP therapeutic position statement on strategies for identifying and preventing pneumococcal resistance.](#) *Am J Health Syst Pharm.* 2004 Nov 15;61(22):2430-5.
94. [Immunization of Health-care Workers.](#) CDC/MMWR December 26, 1997, Vol. 46, No. RR-18.
95. [Prevention and Control of Influenza.](#) CDC/MMWR April 25, 2003, Vol. 52, No. RR-08.
96. [Using live attenuated influenza vaccine for prevention and control of influenza.](#) CDC/MMWR September 26, 2003, Vol. 52, No. RR-13.
97. [Preventing pneumococcal disease among infants and young children.](#) CDC/MMWR October 6, 2000, Vol. 49, No. RR-9.
98. [Prevention of pneumococcal disease.](#) CDC/MMWR April 4, 1997, Vol. 46, No. RR-8.
99. Dragnev KH, Stover D, Dmitrovsky E. [Lung cancer prevention: the guidelines.](#) *Chest* 2003 Jan; 123(1 Suppl):60S-71S.
100. American Society of Health-Systems Pharmacists. [ASHP Therapeutic Position Statement on smoking cessation.](#) *Am J Health-Syst Pharm.* 1999; 56:460-4
101. U.S Department of Health and Human Services, Public Health Services. [Treating tobacco use and dependence.](#) Rockville (MD): U.S. Department of Health and Human Services, Public Health Services; 2000 June 197 p.
102. Williams SC, Morton DJ, Jay KN, Koss RG, Schroeder SA, Loeb JM. [Smoking cessation counseling in U.S. hospitals: a comparison of high and low performers.](#) *J Clin Outcomes Manage* 2005 Jul;12(7):345-352..
103. Schroeder SA. [What to do with a patient who smokes.](#) *JAMA.* 2005 Jul 27;294(4):482-7.